We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more OK
Roche Menu Search Global Web Site : Investors

You are here:

  1. Investors
  2. IR events
Roche
  • Home
  • About Roche
  • Products
  • Sustainability
  • Research & Development
  • Partnering
  • Media
  • Investors
  • Careers
  • Our strategy
  • Financial data
  • Investor updates
  • IR events
  • Downloads
  • Contacts
  • FAQ

ESMO 2012 - Roche conference call for investors and analysts

Webcast Replay

Download mp3

Presentation slides

Investor Updates

Roche’s trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer

Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer

Roche conference call for investors and analysts from ESMO 2012

Share
  • Share via email
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share on Google+
  • Share on Xing
Close

Related links

  • Corporate Governance
  • Annual Report
  • Pipeline
  • FAQ

Service

  • Investor Relations team
  • Send e-mail
  • Subscribe to Roche News
  • Roche Finance Information System
  • © 2018 F. Hoffmann-La Roche Ltd
  • 21.07.2018
  • Legal Statement
  • Privacy Policy

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

  • Twitter
  • LinkedIn
  • Facebook
  • YouTube